The efficacy of serial serum amyloid A measurements for diagnosis and follow-up of necrotizing enterocolitis in premature infants

Simple item page
dc.contributor.buuauthorÇetinkaya, Merih
dc.contributor.buuauthorÖzkan, Hilal
dc.contributor.buuauthorKöksal, Nilgün
dc.contributor.buuauthorAkacı, Okan
dc.contributor.buuauthorÖzgür, Taner
dc.contributor.departmentUludağ Üniversitesi/Tıp Fakültesi/Çocuk Sağlığı ve Hastalıkları Anabilim Dalı.tr_TR
dc.contributor.orcid0000-0002-2148-1160tr_TR
dc.contributor.researcheridAAG-8393-2021tr_TR
dc.contributor.researcheridAAG-8381-2021tr_TR
dc.contributor.scopusid23994946300tr_TR
dc.contributor.scopusid16679325400tr_TR
dc.contributor.scopusid7003323615tr_TR
dc.contributor.scopusid36131105700tr_TR
dc.contributor.scopusid36087775800tr_TR
dc.date.accessioned2021-12-10T06:37:54Z
dc.date.available2021-12-10T06:37:54Z
dc.date.issued2010-08
dc.description.abstractThe purpose of this study was to evaluate the efficacy of serial serum amyloid A (SAA) measurements in diagnosis and follow-up of necrotizing enterocolitis (NEC) in preterm infants. A total of 144 infants were enrolled in this observational study. The infants were classified into three groups: group 1 (infants with NEC and sepsis), group 2 (infants with sepsis), and group 3 (no sepsis and NEC, control group). Data including serial whole blood count (WBC), SAA measurements that were obtained at the initial work-up of NEC and/or sepsis episode (0 day), at 24, 48 h, 7, and 10 day were evaluated. In addition, initial and serial follow-up abdominal radiographies were obtained. A total of 50 infants were diagnosed NEC. Mean SAA values (43.2 +/- A 47.5 mg/dl) of infants in group 1 at 0 h were significantly higher than those in group 2 and group 3. The percentage of infants with abnormal SAA levels was significantly higher in group 1 compared with that in group 2 at 24 h. In addition, the percentage of infants with abnormal SAA levels was slightly but not statistically higher in stage 2 and stage 3 NEC group compared with that stage 1 NEC at 0, 24, 48 h. SAA levels started to decline at 48 h of onset through day 10. The cut-off value for SAA for differentiating NEC from sepsis was 23.2 mg/dl. SAA may be recognized as an accurate laboratory marker in addition to clinical and radiographic findings for NEC diagnosis. It can also be used for determining the severity of NEC and response to therapy in infants with NEC.en_US
dc.identifier.citationÇetinkaya, M. vd. (2010). "The efficacy of serial serum amyloid A measurements for diagnosis and follow-up of necrotizing enterocolitis in premature infants". Pediatric Surgery International, 26(8), 865-841.en_US
dc.identifier.endpage841tr_TR
dc.identifier.issn0179-0358
dc.identifier.issn1437-9813 Other Information
dc.identifier.issue8tr_TR
dc.identifier.pubmed20574758tr_TR
dc.identifier.scopus2-s2.0-77955556083tr_TR
dc.identifier.startpage835tr_TR
dc.identifier.urihttps://doi.org/10.1007/s00383-010-2635-0
dc.identifier.urihttps://pubmed.ncbi.nlm.nih.gov/20574758/
dc.identifier.urihttp://hdl.handle.net/11452/23151
dc.identifier.volume26tr_TR
dc.identifier.wos000280246700011tr_TR
dc.indexed.pubmedPubmeden_US
dc.indexed.scopusScopusen_US
dc.indexed.wosSCIEen_US
dc.language.isoenen_US
dc.publisherSpringeren_US
dc.relation.journalPediatric Surgery Internationalen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergitr_TR
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectDiagnosisen_US
dc.subjectNecrotizing enterocolitisen_US
dc.subjectNewbornen_US
dc.subjectPrematureen_US
dc.subjectSerum amyloid Aen_US
dc.subjectC-reactive proteinen_US
dc.subjectAcute-phase proteinsen_US
dc.subjectNeonatal sepsisen_US
dc.subjectBlood-counten_US
dc.subjectDiseaseen_US
dc.subjectProcalcitoninen_US
dc.subjectParametersen_US
dc.subjectManagementen_US
dc.subjectResponsesen_US
dc.subjectSeverityen_US
dc.subjectPediatricsen_US
dc.subjectSurgeryen_US
dc.subject.emtreeSerum amyloid Aen_US
dc.subject.emtreeArticleen_US
dc.subject.emtreeBlood cell counten_US
dc.subject.emtreeClinical articleen_US
dc.subject.emtreeControlled studyen_US
dc.subject.emtreeFemaleen_US
dc.subject.emtreeHumanen_US
dc.subject.emtreeInfanten_US
dc.subject.emtreeMaleen_US
dc.subject.emtreeNecrotizing enterocolitisen_US
dc.subject.emtreePrematurityen_US
dc.subject.emtreePriority journalen_US
dc.subject.emtreeRadiographyen_US
dc.subject.emtreeSepsisen_US
dc.subject.meshAnalysis of varianceen_US
dc.subject.meshBiological markersen_US
dc.subject.meshBlood cell counten_US
dc.subject.meshChi-square distributionen_US
dc.subject.meshEnterocolitis, necrotizingen_US
dc.subject.meshFemaleen_US
dc.subject.meshHumansen_US
dc.subject.meshInfant, newbornen_US
dc.subject.meshInfant, prematureen_US
dc.subject.meshInfant, premature, diseasesen_US
dc.subject.meshMaleen_US
dc.subject.meshRadiography, abdominalen_US
dc.subject.meshROC curveen_US
dc.subject.meshSensitivity and specificityen_US
dc.subject.meshSepsisen_US
dc.subject.meshSerum amyloid A proteinen_US
dc.subject.scopusNecrotizing Enterocolitis; Prematurity; Intestine Perforationen_US
dc.subject.wosPediatricsen_US
dc.subject.wosSurgeryen_US
dc.titleThe efficacy of serial serum amyloid A measurements for diagnosis and follow-up of necrotizing enterocolitis in premature infantsen_US
dc.typeArticle
dc.wos.quartileQ3en_US

Files

Collections

Web of Science
Scopus